KATIE HEBERT: Open Payments
NPI 1942765326 · THIBODAUX, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,553 in 118 payments from 16 companies in 2025. Trend: 2023 $1,801 · 2024 $2,030 · 2025 $2,553
Food & beverage: $2,459Education: $94
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 21 | $686 |
| ABBVIE INC. | 35 | $581 |
| Gilead Sciences, Inc. | 11 | $183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $173 |
| Dexcom, Inc. | 1 | $165 |
| Janssen Biotech, Inc. | 5 | $151 |
| Phathom Pharmaceuticals, Inc. | 9 | $121 |
| GENZYME CORPORATION | 5 | $106 |
| GlaxoSmithKline, LLC. | 1 | $104 |
| QOL Medical, LLC | 4 | $66 |
Products named: REZDIFFRA, RINVOQ, SKYRIZI, DEXCOM G7 GSS (161), ENTYVIO, TREMFYA, VOQUEZNA, DUPIXENT.
Industry payments across LA — which companies pay providers there.
